Context Therapeutics LLC

Context Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is dedicated to improving the lives of women living with cancer. It engages in developing advanced small molecule and immunotherapy treatments to transform care for hormone-driven breast and gynecological cancers. The firm's robust clinical program for candidate onapristone extended release (ONA-XR) comprises three Phase 2 clinical trials and one Phase 1b/2 clinical trial in hormone-driven breast, ovarian and endometrial cancer, as well as two Phase 0 biomarker pharmacodynamic trials in breast cancer. Its ONA-XR is a novel, first-in-class small molecule under development as a complete antagonist of the progesterone receptor, a key unchecked mechanism in hormone-driven women?s cancers. The company was founded by Martin Lehr and Felix Kim in April 2015 and is headquartered in Philadelphia, PA.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Context Therapeutics said its decision made during the first quarter to focus on developing its preclinical asset CTIM-76 has extended the company's cash runway into late 2024. CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody, is an immunotherapy designed to activate and direct a patient's own immune cells to CLDN6-positive tumors, including lung, ovarian, and testicular, the company noted.

Context Therapeutics says focus on preclinical cancer therapeutic extends cash runway into late 2024

CTIM-76 IND filing on track for Q1 2024 Preclinical data on CLDN6 bispecific antibody CTIM-76 presented at AACR Annual Meeting 2023 Cash and cash equivalents of $29.8 million as of March 31, 2023 PHILADELPHIA, May 10, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company dedicated to improving the lives of patients living with cancer, today announced its financial results for the first quarter ended March 31, 2023, and reported on recent and upcoming business highlights. “During the first quarter of this year, Context announced a portfolio prioritization to focus solely on the development of our preclinical asset CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is an immunotherapy designed to activate and direct a patient's own immune cells to CLDN6-positive tumors, including lung, ovarian, and testicular.

Context Therapeutics Reports First Quarter 2023 Operating and Financial Results

PHILADELPHIA, PA / ACCESSWIRE / April 18, 2023 / Context Therapeutics Inc. (NASDAQ:CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors by harnessing novel and innovative treatment targets such as Claudin 6 (CLDN6). A solid tumor is an unusual tissue growth with no fluid-filled areas.

Significant Unmet Need In Solid Tumors Reported, And How Context Therapeutics (NASDAQ:CNTX) Plans To Make A Difference

Context Therapeutics (NASDAQ:CNTX) Inc announced that an abstract regarding its preclinical candidate, CTIM-76, a Claudin 6 x CD3 bispecific antibody, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, Florida. The clinical-stage biopharmaceutical company said on April 17, 2023, at 4:30 PM EDT, it will host a webinar with its management team and AACR presenter, Dr Rucker, to discuss the results from this presentation, provide updates on the CTIM-76 preclinical program, and answer questions from investors.

Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting, will host webinar

PHILADELPHIA, April 03, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company developing novel treatments for solid tumors, today announced that Chief Executive Officer Martin Lehr will participate virtually in two investor conferences in April 2023. Details of the events are as follows:

Context Therapeutics to Participate in Two April 2023 Investor Conferences

Context Therapeutics (NASDAQ:CNTX) has announced a portfolio prioritization and capital allocation strategy that is expected to extend its cash runway into late 2024.  Releasing its full-year 2022 financial statements, the Philadelphia-based women's oncology company said the resulting changes include discontinuing the development of onapristone extended-release (ONA-XR) and focusing on the development of CTIM-76, its Claudin 6 (CLDN6) bispecific antibody clinical candidate.

Context Therapeutics announces pipeline update with FY 2022 financial results

Company prioritizing pipeline to focus on CTIM-76 development and discontinuing ONA-XR program

Context Therapeutics Reports Full Year 2022 Financial Results and Recent Pipeline Updates

Context Therapeutics says CTIM-76 abstract accepted for presentation at AACR annual meeting

Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET Context to host webinar with AACR presenter on Monday, April 17, 2023, at 4:30 p.m. ET

Context Therapeutics Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Context Therapeutics (NASDAQ:CNTX) Inc has highlighted encouraging clinical responses from its Phase 2 OATH clinical trial evaluating ONA-XR to treat endometrial cancer. The company said that two patients achieved a confirmed partial response among the first 12 patients (9 evaluable) enrolled in the Phase 2 OATH clinical trial evaluating the potential of Context's oral progesterone receptor antagonist onapristone extended release in combination with anastrozole to treat hormone receptor-positive metastatic endometrial cancer.

Context Therapeutics highlights clinical responses from clinical trial evaluating ONA-XR to treat endometrial cancer

ONA-XR initial data signals positive clinical activity and confirmed tumor shrinkage

Context Therapeutics Highlights Clinical Responses from the Phase 2 OATH Clinical Trial Evaluating ONA-XR for the Treatment of Endometrial Cancer

Hillstream Biopharma

Intelligent Bio Solutions Inc

Rent the Runway

Silo Pharma Inc

Sonoma Pharmaceuticals

Spectrum Pharma

Penny Stocks With News Light Up The Scanners This Week This week

7 Top Penny Stocks To Watch With Big News This Week

Stemline Therapeutics

Context Therapeutics (NASDAQ:CNTX) has announced that its clinical trial collaborator, Stemline Therapeutics Inc, a wholly-owned subsidiary of The Menarini Group, has received approval from the US Food and Drug Administration (FDA) for ORSERDU (elacestrant) for the treatment of postmenopausal women or adult men with estrogen receptor–positive (ER+), HER2-negative (HER2-), Estrogen Receptor 1 gene (ESR1)-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. The Philadelphia-based women's oncology company noted that ORSERDU has shown improved efficacy over the current standard-of-care (SOC) treatment, fulvestrant, in patients with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer.

Context Therapeutics says clinical partner Stemline Therapeutics receives FDA approval for ORSERDU to treat certain breast cancers

First endocrine innovation in more than 20 years which  has shown improved efficacy over standard-of-care treatments in patients with advanced breast cancer

Context Therapeutics' Clinical Partner Stemline Therapeutics, a Subsidiary of Menarini Group Receives FDA Approval of ORSERDU™ (elacestrant) in ER+, HER2-, ESR1-mutated Breast Cancer

Context Therapeutics (NASDAQ:CNTX) Inc said it will be collaborating with Lonza, a global development and manufacturing partner to the pharma, biotech, and nutrition industries, to manufacture Context's clinical development candidate CTIM-76. CTIM-76 is a Claudin 6 (CLDN6) x CD3 T-cell engaging bispecific antibody targeting CLDN6 positive tumors, the company noted in a statement.

Context Therapeutics announces manufacturing agreement with Lonza for bispecific antibody targeting Claudin 6 positive cancers

Kronos Bio

Ocugen, Inc.

Sonnet BioTherapeutics

Instil Bio

Hot penny stocks to watch with news this week. The post 5 Hot Penny Stocks To Watch This Week With Big News appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

5 Hot Penny Stocks To Watch This Week With Big News

Lonza to support the development and manufacturing of CTIM-76, Context's CLDN6 x CD3 bispecific antibody clinical candidate

Context Therapeutics and Lonza Enter Manufacturing Agreement for Bispecific Antibody Targeting Claudin 6-Positive Cancers

Context Therapeutics (NASDAQ:CNTX) Inc has indicated in its corporate guidance for 2023 that with ample cash on hand, the company has the scope to advance its pipeline programs. As of September 30, 2022, the Philadelphia-based women's oncology company developing treatments for breast and gynecological cancers, had cash, and equivalents which totaled $39.4 million.

Context Therapeutics has 39.4M cash runway to advance pipeline programs; data update from OATH Phase 2 trial likely in mid-2023

CTIM-76 nominated as Claudin 6 x CD3 bispecific antibody clinical candidate

Context Therapeutics® Highlights 2023 Corporate Priorities and Pipeline Milestones

Context Therapeutics (NASDAQ:CNTX) has announced preliminary Phase 2 data from the ongoing SMILE trial of onapristone extended-release (ONA-XR), the company's novel, first-in-class, potent, orally administered progesterone receptor (PR) antagonist, in metastatic breast cancer. Being conducted in collaboration with the Wisconsin Oncology Network, the Philadelphia-based women's oncology company said the Phase 2 SMILE trial is evaluating ONA-XR in combination with fulvestrant in patients with ER+ (estrogen receptors), HER2- (human epidermal growth factor receptor 2) advanced or metastatic breast cancer who progressed on prior CDK4/6 inhibitor therapy.

Context Therapeutics reports encouraging preliminary Phase 2 data for ONA-XR in metastatic breast cancer

Data presented at San Antonio Breast Cancer Symposium ® demonstrate preliminary 4-month PFS rate of 44% in ongoing Phase 2 trial in second- or third-line metastatic breast cancer

Context Therapeutics® Reports Encouraging Preliminary Phase 2 Data for ONA-XR in Metastatic Breast Cancer

Context Therapeutics (NASDAQ:CNTX) Inc has designated CTIM-76, a T cell-engaging bispecific antibody, as its lead clinical development candidate to target Claudin 6 (CLDN6) positive cancers, the company announced.  The CLDN6 gene is differentially expressed on cancer cells but has no or very low expression in normal, healthy tissue.

Context Therapeutics finds lead clinical development candidate for cancer treatment in CTIM-76

CTIM-76 named as lead candidate to target Claudin 6 positive cancers

Context Therapeutics® Nominates CTIM-76 Bispecific Antibody Candidate to Develop Treatment for Claudin 6-Positive Solid Tumors

Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented Company reports initial ONA-XR data from the ongoing Phase 2 SMILE trial for metastatic breast cancer will be presented

Context Therapeutics® Announces Clinical Updates on ONA-XR to be Presented at 2022 San Antonio Breast Cancer Symposium

Context Therapeutics (NASDAQ:CNTX) Inc, a clinical-stage biopharma company focused on advancing medicines for cancers in women, posted results for the third quarter that revealed ample cash on hand, giving the company scope to advance its pipeline programs. As of September 30, 2022, the Philadelphia-based women's oncology company developing treatments for breast and gynecological cancers, had cash, equivalents, and restricted cash which totaled $39 million.

News for Context Therapeutics LLC Stock (CNTX)